Quantitative Evaluation of Electrocardiogram in Comparison  of Cardioprotection Efficiency in Acute Myocardial Infarction

Tashchuk, V. K.; Іванчук, П. Р.; Tashchuk, M. V.; Polianska, O. S.; Amelina, T. M.; Makoviychuk, Iryna; Onofreychuk, D. I.; Shevchuk, V. A.

doi:10.24061/2413-0737.xxi.2.82.1.2017.20

Cited by 2 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among synthetic cardioprotectors, the group of oxypyridines attracts attention. Succinic acid (butanedioic acid, ethane-1,2-dicarboxylic acid) is a product of the fifth reaction and a substrate of the sixth reaction of the tricarboxylic acid cycle is constantly formed in the body and is oxidized in the citrate cycle with the formation of a large amount of energy that is stored in the form of ATP, as well as preparations of the L-arginine group [23].…”

Section: Medicine and Dentistrymentioning

confidence: 99%

ST2 and copeptine – modern biomarkers for monitoring the effectiveness of treatment of decompensated heart failure in patients after acute myocardial infarction

2022

View full text Add to dashboard Cite

The aim of the study was to increase the efficiency of diagnostic methods to find means to improve the treatment of patients with decompensated heart failure in the post-infarction period. Materials and methods. This study is based on an examination of 120 patients with decompensated HF (60 patients with STEMI and 60 with non-STEMI). Patients with previous STEMI complicated by decompensated heart failure were divided into groups, depending on their treatment. The studied groups were homogeneous in terms of age, sex, the severity of the course of the disease, duration of the post-infarction period, and the presence of clinical manifestations of decompensation. The patients were observed on the first day after hospitalization, after 1 and 2 months after treatment. Copeptin serum levels were assayed using the EK 065-32, EIA Copeptine kit (RayBiotech, Inc., USA). ST-2 in blood serum was determined with the help of the Presage ST-2 kit (Critical Diagnostics, USA). The level of ST2 was determined in ng/ml. Results. We analysed the effect of therapy on the level of ST2 in the blood serum of examined patients with STEMI and non-STEMI complicated by decompensated heart failure. All the treatment regimens we proposed led to a significant decrease in the level of this peptide in blood serum after the end of the treatment. In patients of group I who received basic therapy drugs, the average ST2 concentration was (49.47±1.77) ng/ml before treatment. After 1 and 2 months of therapy, it was (44.92±1.22) ng/ml and (41.67±1.18) ng/ml, respectively (p˂0.05). The patients with decompensated heart failure after non-STEMI from group I had a copeptin level of (18.13±0.10) pg/ml before treatment and probably decreased to levels of (16.29±0.15) pg/ml and (15.09±0.14) pg/ml after 1 and 2 months under the influence standard therapy. Conclusions. We found the dependence of copeptin and ST2 levels on decompensated HF in the early and late post-infarction periods. It was established that the use of the therapy with a combination of the studied drugs led to a more intense decrease in serum copeptin, compared to therapy with succinic acid, arginine drugs, and standard therapy (p˂0.05). Using a differentiated treatment algorithm for patients with decompensated heart failure in the post-infarction period, copeptin and ST2 in blood serum increases the effectiveness of treatment and prevents complications.

show abstract

Section: Medicine and Dentistrymentioning

confidence: 99%

ST2 and copeptine – modern biomarkers for monitoring the effectiveness of treatment of decompensated heart failure in patients after acute myocardial infarction

2022

View full text Add to dashboard Cite

show abstract

“…Це істотно підвищує чутливість і специфічність ЕКГ-дослідження, тому доцільним є оцінювання показника першої похідної -відношення максимальних швидкостей (ВМШ) за допомогою власного програмно-діагностичного комплексу «Смарт-ЕКГ» (свідоцтво про реєстрацію авторського права № 73687 від 05.09.2017 р.) [5][6][7][8][9][10]. За допомогою програми «Смарт-ЕКГ» також можна аналізувати спрямування сегмента ST після точки J, що при STEMI змінює геометрію, оскільки при некротизації міокарда утворюється ділянка пошкодження та виникає різниця потенціалів між здоровою та ураженою тканиною, формується елевація сегмента ST з наступним зниженням і формуванням інвертованого зубця Т [11].…”

unclassified

ST-segment elevation myocardial infarction and the clinical significance of differentiated electrocardiogram

Tashchuk¹,

Malinevska-Biliichuk²,

Іванчук³

et al. 2023

ZMJ

View full text Add to dashboard Cite

Aim. To evaluate the markers of changing dynamics recorded by digital processing of routine ECG using own diagnostic complex software “Smart-ECG” in patients with ST-segment elevation myocardial infarction (STEMI) based on the results of a 40-day follow-up. Materials and methods. The main group consisted of 20 patients with STEMI according to the ESC guidelines (2017) (mean age of males 56.11 ± 11.62, n = 10; mean age of females 58.22 ± 13.11, n = 10). ECG were analyzed using own developed diagnostic complex software “Smart-ECG” on the 1st, 10th, 40th day after STEMI. The first derivative of T wave – ratio of maximum velocity (MVR), inclination angle (β) and inclination height (H) of ST segment was calculated. The control group – 20 apparently healthy people. Results. MVR indicators decreased by 61.90 %, 68.20 % and 51.48 % on the 1st, 10th and 40th day, respectively, after STEMI as compared to those of the control group (p < 0.01). At the moment of the maximum ST segment elevation, the height (H) of ST inclination was 347.7 % increased (p < 0.01); on the 40th day, H was 25 % increased, close to control indicators, with ST segment shift to isoline (р > 0.05). During the acutest period, the angle β increased by 172.2 % (p < 0.01) and then decreased by 15.8 % at the recovery phase, but insignificantly. Conclusions. Self-developed medical software “Smart-ECG” for qualitative evaluation of ECG is an effective tool to diagnose pathological changes in the myocardium, makes it possible to improve the specificity, sensitivity and prognostic significance of ECG in STEMI. The significant decrease in MVR has been detected at all stages of STEMI, which was associated with a violation of electrogenesis in the repolarization phase; the critical increase in ST slope indicators (angle β and height H) on the 1st day has been found as a characteristic of ST elevation, as well as its decrease on the 40th day as a sign of reduced potential difference between healthy and damaged areas of the myocardium during the recovery stage.

show abstract

Quantitative Evaluation of Electrocardiogram in Comparison of Cardioprotection Efficiency in Acute Myocardial Infarction

Cited by 2 publications

References 4 publications

ST2 and copeptine – modern biomarkers for monitoring the effectiveness of treatment of decompensated heart failure in patients after acute myocardial infarction

ST2 and copeptine – modern biomarkers for monitoring the effectiveness of treatment of decompensated heart failure in patients after acute myocardial infarction

ST-segment elevation myocardial infarction and the clinical significance of differentiated electrocardiogram

Contact Info

Product

Resources

About